Greenwich LifeSciences reports record patient screening for Phase III trial
Greenwich LifeSciences (NASDAQ:GLSI) surged ahead in its clinical timeline on Tuesday, reporting a significant acceleration in patient recruitment for its pivotal Phase III breast cancer study.











